Salbutamol and related beta-2 sympathomimetic drugs have been used in Australia recently for the inhibition of premature labour and also to prevent uterine activity in acute foetal emergencies during labour. General anaesthesia in these situations presents the anaesthetist with a number of pharmacological difficulties, which can have profound effects on both mother and neonate. The use of beta-blockers to correct the cardiovascular and metabolic instability is discussed and recommendations are made for their use in association with anaesthesia for operative delivery. Ante-natal beta-blockade of mother may increase the morbidity and possibly the mortality of an already at risk pre-term neonate. The case report illustrates some of the hazards associated with salbutamol, obstetrics and anaesthesia.
INTRODUCTION
Since pre-term infants are most at risk from respiratory distress syndrome (RDS), many methods to inhibit premature labour have been tried in order to gain time to accelerate foetal lung maturity. Interest in this came about following the reports of Ligginsl,2 and Howie 2 that glucocorticoids given to the mothers of pre-term infants resulted in a dramatic decrease in the incidence and severity of RDS. During the late 1960s, ethanoP was reinvestigated and in 1970 Baillie et at" reported orciprenaline as an alternative. Liggins and Vaughan 5 in Auckland then studied salbutamol which was shown to be effective and this led to its widespread use in many obstetric units. More recently, newer adrenergic agents are making their appearance in centres outside Australia. 6 However, all practitioners in obstetrics should be well aware that these pharmacological methods are not without hazard. 7 
SALBUTAMOL
Salbutamol is classified as a selective beta-2 agonist of the phenylethylamine type ( Figure  1 ). Unlike the catecholamines, it is not metabolised by catechol-o-methyl transferase. (Ritodrine is a similar agent currently under trial.) Although its action is regarded as beta-2 selective, this is clearly a dose-related effect, for it has become apparent that with the dose regimes used to inhibit labour specificity is gradually lost. 20 Salbutamol has a plasma half-life of about 30 minutes, but in the woman in labour, an effective half-life of about 3 hours if renal and hepatic functions are normal. It is partly conjugated in the liver to an inactive glucuronide which is then excreted with the parent drug in the urine. Protein binding in plasma is minimal, and free placental transfer has been shown in mammals and probably also occurs in man. s Salbutamol is given by intravenous infusion in doses ranging from 1 to 50 micrograms/minute,5.9,1O a dosage regime far in excess of that seen in its usual role as a bronchodilator. Salbutamol in this dose causes a variety of symptoms and signs ( Table 1) , some of which may be centrally mediated. For example, the muscle tremor may be centrally mediated, or it may be an indirect metabolic effect. 9 The significance of this in relation to the use of neuromuscular blocking drugs is unknown. Nausea and vomiting have also been reported. Beta-l effects (e.g. tachycardia) of salbutamol are used in most centres as a guide to the upper limit of dosage, which in our unit commonly occurs at an infusion rate of about 20 f.lg/minute.
Recently in some units bolus doses of salbutamol have been used to cause uterine atony in cases of severe foetal distress or prolapse of the cord, so that further contractions do not jeopardise the foetus before anaesthesia and an operative delivery can be instituted. Anaesthesia in this situation was reported first by KnightIl in 1977, and a further case has been reported by Schoenfeld et al. 12 
CASE REPORT
Induction and pre-delivery maintenance of anaesthesia poses some serious problems when it is necessary to perform a caesarean section with high blood levels of salbutamol. The following case illustrates these problems.
The patient, 27-year-old, grav. 4/para. 3, presented in labour at 29 weeks gestation. Her ante-natal course had been complicated by slight bleeding per vaginam and an ultrasonic examination revealed a grade 2 placenta praevia. Soon after admission to the labour ward, salbutamol was commenced by intravenous infusion. Table 2 shows the course of the infusion and its effects. After 17 hours there was a minor ante partum haemorrhage and caesarean section was decided upon. Prior to induction haemoglobin was 10.4 g/l00 ml and bleeding and coagulation screen was normal, blood pressure 130/70 mmHg, pulse rate 140 beats/minute and regular. ECG showed sinus tachycardia. Respiratory rate was 26/minute breathing oxygen via C.I.G. mask (FIO, approx. 0.4).
After further oral antacid, pre-oxygenation with FIO, 1.0 and left lateral tilt of 15°, anaesthesia was induced with thiopentone 225 mg and intubation effected with suxamethonium and cricoid pressure. Predelivery anaesthesia was maintained with 50070 nitrous oxide in oxygen, intermittent thiopentone and d-tubocurarine. Halothane was not used. The induction-delivery interval was 18 minutes, during which time her cardiovascular state remained stable and she received one unit of whole blood. The infant was delivered without difficulty and the third stage managed with 5 units of syntocinon intravenously. Anaesthesia was then deepened with papaveretum 20 mg intravenously over 5 minutes and nitrous oxide increased to 65%. As the uterus contracted, the blood pressure fell to approximately 80 mmHg systolic and the heart rate increased to 190 beats/minute with occasional premature ventricular contractions (PVC) which increased in frequency. Sinus beats exhibited biphasic T waves. Propranolol 3.5 mg was given intravenously over the ensuing 5 minutes in 0.5 mg increments and the ECG and cardiovascular parameters reverted to normal. The remaining operative course was uneventful. Intra-operative blood loss was of the order of 800 ml and total replacement was two units of whole blood together with some crystalloid during the 2 hour peri-operative period.
The infant had Apgar scores (minus colour) of 6 and 8 and subsequently suffered only mild respiratory distress syndrome. Mother's recovery was uneventful. Blood sugar levels, acid/base status and ECG remained normal postoperatively and there was no recall by the patient of operative events.
DISCUSSION
This case, although complicated by antepartum haemorrhage and blood transfusion, illustrates well the non-specific effects of high doses of salbutamol. The patient demonstrated similar responses to those reported by Knight, 11 viz. falling cardiac output in the face of increased pre-load during the third stage and the inability of the heart to respond to increasing work load. Whether syntocinon can Anaesthesia and Intensive Care, Vol. VllI, No. J, February, 1980 be implicated in the above case is not clear, for in Knight's case ergometrine was used.
All obstetric anaesthetists should be aware of the non-specific adrenergic effect of salbutamol when it is used to prevent premature labour. Approximately 5OJo of all true labours may be classed as premature, i.e. less than 37 weeks gestation. 13 In a large centre therefore about 150-200 such cases each year are to be expected. Not all of these will receive salbutamol and of those who do, only a few will require anaesthesia. Thus the problem is not common, but when anaesthesia is required it is almost invariably at short notice.
The problems associated with anaesthesia in these patients are:
(i) Fluids and electrolytes. Many of these women receive large quantities of 5% dextrose in water as intravenous maintenance, and because of the increased renal blood flow, increased sweating and increased respiratory losses, examination of bio-chemical parameters (serum Na, K, Cl) should be undertaken periodically during the salbutamol treatment. Blood loss may also occur.
(ii) Carbohydrate metabolism. Glycolysis and glycogenolysis are increased by salbutamol, presumably in the foetus as well as mother, so an adequate supply of glucose should be given preferably intravenously and blood sugar levels closely watched. The 'pre-diabetic' status of many pregnant women is an additional factor here, and keto-or lactic-acidosis a possibility.
(iii) Oxygen consumption is increased in line with the general increase in metabolism and sympathetic activity and inadequate oxygen flux may lead to hypoxia, acidosis and myocardial ischaemia. These problems will be reflected in the foetus when they occur in mother. (iv) Anaesthetic agents. Because they induce an increase in sympathetic tone, the use of ketamine or cyclopropane in such patients is contraindicated. Thiopentone or methohexitone would appear to be the agents of choice, care being taken with dosage and speed of injection because of the brittle cardiovascular balance. The common practice of supplementation of the inhalational agents with 0.3-0.5 MAC halothane as advocated by Moir l4 may be hazardous in the face of a hyperactive sympathetic nervous system, and could lead to serious ventricular arrhythmias. On present evidence, it may be safer to supplement with intermittent barbiturate or even opiate. Enflurane would seem to be safer than halothane. I; (v) Oxytocic drugs. Although synthetic oxytocin has some pressor activity this can be minimised by dosage and rate of injection. 16 Ergometrine, however, is contra-indicated because of an increase in cardiac work following its administration. (vi) Beta-blockade. The use of beta-blockers would seem to be the logical answer to the problems caused by salbutamol, but if this is undertaken before delivery, it may affect the neonate and lead to increased morbidity. Propranolol, the only beta-blocker to be used widely during pregnancy, has been shown to have serious effects on the newborn, as listed in Table 3 . The bradycardia can be extremely resistant to the usual methods of treatment and if profound enough could result in persistence of a foetal circulation. 17 Hypoglycaemia and hypothermia may also result but can be controlled in a well equipped paediatric unit. The half-life of propranolol in the neonate can be expected to be prolonged, particularly when pre-term, hence these problems are liable to persist for up to 36 hours after delivery. Bradycardia.
3.
Inability to increase metabolic rate.
-basal.
-brown fat lipolysis.
-consequent increased risk of hypothermia.
4.
Reduced metabolism of propranolol.
5.
Potentiation of non-depolarizing neuro-muscular blockade.
Thus, it would seem desirable to postpone beta-blockade until after delivery, and then use it only if there are strong indications. In this patient, ECG evidence of cardiac ischaemia together with pump failure due to dysrhythmias constituted such an indication. If used after delivery, beta-blockers may have effects on the mother extending into the postoperative period. She may have a reduced ability to cope with a post partum haemorrhage and possibly hypoglycaemia. (vii) Muscle relaxants. The muscle relaxant requirements for anaesthesia in patients heavily dosed with salbutamol appear to be little different from the normal pregnant patient. It is known, however, that propranolol will potentiate the block induced by non-depolarising agents l8 by a quinidine-like action. Harrah l9 in 1970 showed that this only occurred with large doses of propranol in adult man, but it may be important for the neonate if the mother receives a beta-blocker before delivery. It may be better to use a succinylcholine infusion for pre-delivery muscle relaxation, where beta-blockers have been given. (viii) Monitoring. Mention has been made throughout the discussion of the need to monitor ECG, blood glucose, serum electrolytes, blood gases and acid/base balance, and to replace blood losses adequately, preferably with the aid of central venous pressure manometry.
(iv) Local Anaesthesia. In most instances, the urgency does not permit the use of an epidural block, but if regional anaesthesia is to be used, the monitoring should be the same as for general anaesthesia with particular emphasis on the circulatory status of the mother. CONCLUSION The obstetric use of salbutamol as an inhibitor of premature labour has become accepted clinical practice. It is not without hazard however, to mother or baby especially when its use is combined with general anaesthesia, and care must be taken to minimise the unwanted and dangerous beta-2 and beta-l agonist effects of the drug.
